Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer

Trial Profile

Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
  • Indications Breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCENT
  • Sponsors Immunomedics
  • Most Recent Events

    • 13 Nov 2017 According to an Immunomedics media release, abstract related to data from this trial were posted online and will be presented at the 2017 SABCS.
    • 09 Nov 2017 According to an Immunomedics media release, first patient has been dosed in this trial.
    • 18 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top